ATE485055T1 - Adjuvierte antigene meningokokkenzusammensetzungen - Google Patents

Adjuvierte antigene meningokokkenzusammensetzungen

Info

Publication number
ATE485055T1
ATE485055T1 AT02788442T AT02788442T ATE485055T1 AT E485055 T1 ATE485055 T1 AT E485055T1 AT 02788442 T AT02788442 T AT 02788442T AT 02788442 T AT02788442 T AT 02788442T AT E485055 T1 ATE485055 T1 AT E485055T1
Authority
AT
Austria
Prior art keywords
adjuved
antigen
meningococcal
compositions
meningococcal compositions
Prior art date
Application number
AT02788442T
Other languages
English (en)
Inventor
Mariagrazia Pizza
Marzia Giuliani
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE485055T1 publication Critical patent/ATE485055T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02788442T 2001-12-04 2002-12-04 Adjuvierte antigene meningokokkenzusammensetzungen ATE485055T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129007.1A GB0129007D0 (en) 2001-12-04 2001-12-04 Adjuvanted antigenic meningococcal compositions
PCT/IB2002/005662 WO2003047619A2 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions

Publications (1)

Publication Number Publication Date
ATE485055T1 true ATE485055T1 (de) 2010-11-15

Family

ID=9926977

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02788442T ATE485055T1 (de) 2001-12-04 2002-12-04 Adjuvierte antigene meningokokkenzusammensetzungen

Country Status (11)

Country Link
US (2) US20060008476A1 (de)
EP (1) EP1448230B1 (de)
JP (2) JP4414226B2 (de)
AP (1) AP2004003074A0 (de)
AT (1) ATE485055T1 (de)
AU (1) AU2002353417A1 (de)
CA (1) CA2468935C (de)
CY (1) CY1111114T1 (de)
DE (1) DE60238075D1 (de)
GB (1) GB0129007D0 (de)
WO (1) WO2003047619A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
EP1261723B1 (de) * 2000-02-28 2008-02-27 Novartis Vaccines and Diagnostics S.r.l. Hybride expression von neisseria proteinen
WO2002098368A2 (en) * 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CN1816350B (zh) * 2002-05-14 2010-11-10 莱顿大学 带有几丁聚糖佐剂和/或脑膜炎抗原的粘膜疫苗
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
EP3246044B2 (de) 2010-08-23 2024-04-10 Wyeth LLC Stabile formulierungen von neisseria-meningitidis-rlp2086-antigenen
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
WO2012059592A1 (en) * 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for delivering a therapeutic or imaging agent to the brain
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2013132452A2 (en) 2012-03-09 2013-09-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP2877492A1 (de) 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Cd147 als rezeptor für pilusvermittelte adhäsion von meningokokken an gefässendothelzellen
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
CA3123887A1 (en) * 2018-12-21 2020-06-25 Griffith University Compositions, methods and uses for eliciting an immune response
BR112022004921A2 (pt) 2019-09-27 2022-07-19 Pfizer Composições para neisseria meningitidis e métodos das mesmas
WO2021067628A2 (en) * 2019-10-01 2021-04-08 Beth Israel Deaconess Medical Center, Inc. Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2308606A1 (en) * 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
ATE446368T1 (de) * 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
WO2000018434A1 (en) * 1998-09-30 2000-04-06 American Cyanamid Company Mutant cholera holotoxin as an adjuvant
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.

Also Published As

Publication number Publication date
JP2009155344A (ja) 2009-07-16
US20100233205A1 (en) 2010-09-16
AU2002353417A1 (en) 2003-06-17
EP1448230B1 (de) 2010-10-20
JP2005511662A (ja) 2005-04-28
CY1111114T1 (el) 2015-06-11
DE60238075D1 (de) 2010-12-02
US20060008476A1 (en) 2006-01-12
JP4414226B2 (ja) 2010-02-10
WO2003047619A2 (en) 2003-06-12
CA2468935C (en) 2013-02-05
AP2004003074A0 (en) 2004-06-30
EP1448230A2 (de) 2004-08-25
CA2468935A1 (en) 2003-06-12
WO2003047619A3 (en) 2003-10-23
GB0129007D0 (en) 2002-01-23

Similar Documents

Publication Publication Date Title
ATE485055T1 (de) Adjuvierte antigene meningokokkenzusammensetzungen
ATE553775T1 (de) Impstoffzusammesetzung
FI20010780A0 (fi) Parannetut koostumukset
NO20026175L (no) Vaksinesammensetning
PL368370A1 (pl) Kompozycja glifosatu
IS6915A (is) Lyfjablanda
IS7297A (is) Streptococcis Pneumoniae bóluefni
DK1427444T3 (da) West-nil-vaccine
BR0210619A (pt) composição
IS7081A (is) Lyfjablanda
NO20033882L (no) Vaksine
DE60224595D1 (de) Fluoroelastomere
EE200300569A (et) CD44v6-spetsiifilised antikehad
DE60229463D1 (de) Fluoroelastomere
EE200300480A (et) Pregabaliini-laktoosi konjugaadid
EP1420818A4 (de) Antigene zusammensetzungen
DE50202942D1 (de) Basenhältige mikronährstoffmischung
EP1313839A4 (de) Immunsystem steigernde zusammensetzungen
DE50206933D1 (de) Zweimassenschwungrad
EP1454914A4 (de) Tumorantigen
DE60213119D1 (de) Zweimassenschwungrad
ITTO20020744A0 (it) Composizione
DE50100362D1 (de) Kreuzscheibenkupplung
DE60217632D1 (de) Wandnachbildungen
EE200300377A (et) Loomulikud HI-viiruse vastased antikehad

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties